id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-326169-delehk6x	CJ Jorgensen, Sarah	Baricitinib: A review of pharmacology, safety and emerging clinical experience in COVID‐19	2020-06-15		.txt	text/plain	2704	180	44	The lack of reliable biomarkers to monitor patients' immune status as illness evolves complicates deployment of immunosuppressive drugs like baricitinib. In this article we review available data on baricitinib with an emphasis on immunosuppressive and antiviral pharmacology, pharmacokinetics, safety and current progress in COVID‐19 clinical trials. In population PK analyses, body weight did not have a clinically meaningful 250 impact on baricitinib clearance, however obese RA patients have been reported to have lower 251 response rates. Thrombocytosis Accepted Article 499 treatment strategies aimed at attenuating both pathogen virulence and the pro-inflammatory 500 phenotype seen in the many critically ill patients with COVID-19. 5, 9, 12, 13, 20, 56 As detailed in this 501 review, baricitinib pairs immunosuppressive properties with antiviral activity making it a logical 502 candidate for further evaluation in COVID-19 clinical trials . Baricitinib therapy in 626 COVID-19: A pilot study on safety and clinical impact Impaired type I interferon activity and exacerbated 662 inflammatory responses in severe Covid-19 patients	./cache/cord-326169-delehk6x.txt	./txt/cord-326169-delehk6x.txt